33119-72-1

Basic information

• Product Name: 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE
• Synonyms: 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HCL;1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE;1-Amino-3,3-dimethyl-2-butanonehydrochloride
• CAS NO: 33119-72-1
• Molecular Formula: C6H14ClNO
• Molecular Weight: 151.63
• Mol File: 33119-72-1.mol
• Article Data: 15

Chemical Properties

• Melting Point: 205 °C
• Boiling Point: 198.4 °C at 760 mmHg
• Flash Point: 73.8 °C
• Appearance: /
• Vapor Pressure: 0.304mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE(33119-72-1)
• EPA Substance Registry System: 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE(33119-72-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 33119-72-1(Hazardous Substances Data)

Usage

Description

1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE, also known as 1-Amino-3,3-dimethylbutan-2-one hydrochloride, is an organic compound with the chemical formula C6H13NO?HCl. It is a white crystalline solid that is soluble in water and has a molecular weight of approximately 157.64 g/mol. 1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE is a key intermediate in the synthesis of various pharmaceuticals and has been found to possess significant biological activities.

Uses

Used in Pharmaceutical Industry:
1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE is used as a key intermediate in the synthesis of cyclin-dependent kinase 2 (CDK-2) inhibitors for their application as selective antitumor agents. These CDK-2 inhibitors play a crucial role in the regulation of the cell cycle and have shown potential in the treatment of various types of cancer by selectively targeting and inhibiting the activity of CDK-2, thereby preventing uncontrolled cell proliferation and tumor growth.

InChI:InChI=1/C6H13NO.ClH/c1-6(2,3)5(8)4-7;/h4,7H2,1-3H3;1H

Upstream product

• 171974-64-4 2,4-Bis(dimethylethyl)-2-methyl-2,5-dihydro-1H-imidazole 
• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 56658-35-6 1-phthalimido-3,3-dimethyl-butan-2-one 
• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 5469-26-1 1-Bromopinacolon 

Downstream Products

• 333389-44-9 α-N-2-(chloroacetylamino)pinacolone 
• 345627-80-7 SNS-032 
• 345629-23-4 tert-butyl 4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-carbamoyl)piperidine-1-carboxylate 
• 1333327-16-4 2-bromo-N,N'-bis-(3,3-dimethyl-2-oxobutyl)-isophthalamide 

Relevant articles and documents

MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES

An organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one metal-carbene complex comprising one, two or three specific bidentate diazabenzimidazole carbene ligands;a light-emitting layer comprising said metal-carbene complex as emitter material, preferably in combination with at least one host material;the use of said metal-carbene complex in an OLED;an apparatus selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, units in items of clothing, units in handbags, units in accessoires, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer;the metal-carbene complex comprising one, two or three specific bidentate diazabenzimidazole carbene ligands mentioned above and a process for the preparation of said metal-carbene complex.

Long-range diastereoselectivity in an Ugi reaction: Stereocontrolled and diversity-oriented synthesis of tetrahydrobenzoxazepines

Salicylaldehydes and protected 1,2-amino alcohols have been convergently converted into a series of 2,3-dihydrobenzo[f][1,4]oxazepines, which undergo an Ugi-Joullie multicomponent reaction with unusual long-range diastereoselectivity. This protocol allows

CDK INHIBITORS

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.